DFDA

Galcanezumab

Treatment for Cluster Headache

Typical Dosage: 300 mg subcutaneous monthly

Effectiveness
85%
Safety Score
85%
Clinical Trials
3
Participants
1.2K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
85
DangerousModerateSafe
Treatment Details
Dosage Range
300 mg subcutaneous monthly
Time to Effect
1 week
Treatment Duration
3-6 months per cluster period
Evidence Quality
HIGH
Number Needed to Treat (NNT)
4(Treat 4 patients to see 1 additional successful outcome)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$34,500
Monitoring:$300
Side Effect Mgmt:$50
Total Annual:$34,850
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$200,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$53,615
Prescription Access Economics
Annual Societal Loss per Patient
$-21,130
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$300/year
Time Cost
$100/year
Travel + wait time
Insurance Admin Cost
$120/year
Prior auth, claims
Rx Price
$34,500/year
Potential OTC Price
$24,150/year
Estimated if OTC available
Early Treatment Benefit
+30000.00 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOW
Missed Diagnosis Risk
MODERATE
Galcanezumab Outcomes

for Cluster Headache

Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+65%
Common Side Effects
Injection site reaction
+15%
Constipation
+3%

Sources:

hcplive.com
neurologylive.com
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
3 completed trials for Galcanezumab in Cluster Headache

A Study of LY2951742 (Galcanezumab) in Participants With Cluster Headache

NCT02797951COMPLETEDPHASE3
View Study
165 participants
INTERVENTIONAL
Phoenix, United States +39 more
Started: Jul 13, 2016

A Study Of Galcanezumab In Participants With Episodic Cluster Headache

NCT02397473COMPLETEDPHASE3
View Study
109 participants
INTERVENTIONAL
Los Angeles, United States +46 more
Started: May 22, 2015

A Study of Galcanezumab in Participants With Chronic Cluster Headache

NCT02438826COMPLETEDPHASE3
View Study
240 participants
INTERVENTIONAL
Phoenix, United States +47 more
Started: Jun 18, 2015